The study was undertaken to validate a clinical model for predicting the medical risk of cancer patients with fever and neutropenia.
stable and whose risk of medical complications is low, they could be safely discharged to receive antibiotics at home, thereby decreasing costs," freeing inpatient beds, and allowing patients to enjoy a familiar home environment. Without a reliable means of identifying low-risk patients at the onset of fever and neutropenia, early discharge of patients to home antibiotics may put some patients at unacceptable risk. This potential risk makes the lowering of the standard of care for these patients (by treating them in the less intensively supervised medical environment of home) ethically, medically, and legally difficult, despite the potential benefits of home care. However, once a valid decision rule for identifying patients with fever and neutropenia at sufficiently low risk is available, ethical and medical-legal issues arising from substituting a less-intensive therapy for a standard treatment become more manageable. The validated risk assessment model affords physicians and patients with a realistic and accurate assessment of the level of risk and allows them to make informed judgements about whether to enter an experimental program of outpatient therapy.
Therefore, a reliable approach for identifying patients at low risk early in their course appears necessary for a safe, effective, and widely adopted early-discharge strategy.
We recently developed a prediction model to identify low-risk patients with fever and neutropenia in a retrospective study of 261 episodes of fever and neutropenia at the Dana-Farber Cancer Institute (DFCI). Using
RISK IN FEVER AND NEUTROPENIA
clinical variables that could be assessed within 24 hours of presentation with fever and neutropenia, the model predicted the occurrence of any acute medical condition likely to require emergent medical attention at any time in the patient's subsequent hospital course. 7 However, this model had been developed on a single training set of patients at only one institution. To validate the risk assessment model and improve its generalizability, we performed a prospective, two-center validation study, with blinded review of risk factors and end points.
PATIENTS AND METHODS

Patient Selection and Clinical Management
We prospectively identified 444 consecutive cancer patients at DFCI (383 patients) and at Miriam Hospital, Providence, RI (61 patients), with fever (temperature Ž 100.5 0 F) and neutropenia (granulocyte count < 500/1 L, including polymorphonuclear leukocytes, bands, metamyelocytes, myelocytes, and promyelocytes) by regular review of computerized reports of granulocyte levels and hospital admission lists between September 1, 1987, and July 4, 1989 (no accrual occurred at DFCI between March 1, 1988, and July 5, 1988) . Broad-spectrum intravenous antibiotic therapy was administered, usually consisting initially of either a semisynthetic penicillin and an aminoglycoside or ceftazidime alone, unless additional clinical information suggested supplemental antibiotic coverage. All outpatients were admitted for therapy. Fevers documented only by patients at home and neutropenia documented within 24 hours after entering the study in chemotherapytreated patients with falling granulocyte counts were acceptable. Because clear resolution of the episode of neutropenia is unpredictable and difficult to identify, patients with chronic neutropenia were excluded. The research protocol was approved by the institutional review boards of DFCI and Miriam Hospital.
Data Collection and Blinded Review
All initial data collection was performed prospectively by two of us (J.A.T. and R.D.S.). Because this method of data collection precluded assessing risk factors independently of outcomes, a separate, blinded review was performed for all subjects who were outpatients when fever and neutropenia occurred (for medical complications and for the primary risk factors, serious concurrent comorbidity and uncontrolled cancer) and for a random 10% sample of the remaining patients who were already hospitalized for other reasons and, thus, were not candidates for an early-discharge program (for medical complications only). Review was performed by another study physician using nonoverlapping photocopied portions of the medical record of the first 24 hours after presentation (for assessing risk factors) or the remaining hospital course (for assessing complications). When the initial assessment and the blinded review were in disagreement, a third and deciding assessment was made after reviewing the conflicting assessments and the appropriate portion of the medical chart. The frequency of interrater conflicts was 13% for assessing comorbidity (K = .64), 8% for assessing uncontrolled cancer (K = .77), and 6% for assessing medical complications (K = .78).
Control of cancer. Control of cancer was assessed using diagnostic information available to the treating physician, including radiographs up to and including the time of presentation and, for leukemia, the most recent bone marrow biopsy. For patients with leukemia, uncontrolled cancer was defined as the absence of documented complete remission. For patients with lymphoma or solid tumors, uncontrolled cancer was defined as either development of new lesions, 25% or more enlargement of a measurable lesion while on chemotherapy, or premature termination of chemotherapy due to other evidence of failure (usually progressive cancer symptoms) by the primary medical oncologist. Patients with evidence of disease progression when not receiving active systemic therapy were rated as not having uncontrolled cancer.
Comorbidity. Patients were judged to have serious concurrent comorbidity other than fever and neutropenia if they had another medical condition that independently required inpatient observation or therapy. Predefined conditions meeting these criteria included hypotension (systolic blood pressure < 90 mm Hg), altered mental status, respiratory failure (partial pressure of oxygen [Po,] < 60 torr, adjusted for hyperventilation), uncontrolled bleeding with severe thrombocytopenia (platelet count < 40,000/ 1 L), inadequate outpatient fluid intake or pain control, suspected spinal cord compression, and symptomatic hypercalcemia. In addition, during review of the patient courses, the following other comorbid conditions were rated as requiring hospitalization for outpatients without predefined comorbidity: the need for induction therapy for leukemia (seven patients); serious localized infections (seven patients); acute abdomen (two patients); new deep venous thrombosis (two patients); witnessed syncopal episode (one patient); obstructed jejunostomy tube (one patient); symptomatic, borderline respiratory status (P 0 2 62 mm Hg; one patient); a combination of hyperglycemia, severe anemia, apd profound weakness (one patient); and fever and neutropenia shortly after admission for high fever (104'F) and suspected perirectal abscess in two patients, respectively.
Medical complications. Subsequent life-threatening medical complications included the following predefined categories: hypotension or respiratory failure (as defined above), new cardiac tachydysrhythmia or electrocardiographic changes, altered mental status leading to diagnostic work-up, new focal neurologic abnormalities persisting 24 hours, hemorrhage resulting in > 3 units of blood transfusion within 24 hours, congestive heart failure documented by chest radiograph, and emergency surgery. In review of patient courses, additional life-threatening complications were identified in 33 patients, including serious, acute intrathoracic complications, acute abdomen or bowel obstruction, acute renal failure, and a variety of other medical emergencies. Fourteen patients experienced only these "other" complications. These included severe abdominal pain (acute abdomen; three patients), clinical pulmonary edema with nonradiographic documentation (two patients), acute renal failure (two patients), recurrent bronchospasm (one patient), probable pulmonary embolus (one patient), cardiac tamponade (one patient), axillary vein thrombosis (one patient), severe hypernatremia (one patient), diabetic ketoacidosis (one patient), and symptomatic malignant hypercalcemia (one patient). Death was recorded if the patient died during the study admission (27 patients) or was transferred to another acute care hospital and subsequently died (seven patients). For patients with limitations imposed by patients or their families on the diagnostic and/or therapeutic response to major clinical events, death could occur without a recorded medical complication, Risk groups. Using criteria developed in our prior study, patients were placed in three high-risk groups, based on their status at diagnosis of fever and neutropenia. Patients who were already inpatients comprised group I. Outpatients who demonstrated serious concurrent comorbidity within 24 hours of presentation comprised group II. Outpatients without serious concurrent comorbidity but with uncontrolled cancer comprised group III. The remaining patients, who had none of these high-risk features, comprised group IV. 7 
Statistical Methods
Stepwise forward logistic regression analysis of presenting clinical characteristics was performed to model the independent predictors of subsequent serious medical complications, using a significance level of P less than .05 (ie, at each step the model was recalculated with each factor not previously included, and the factor with the lowest P value < .05 was added for the next step). The custom statistical software package Data Analysis System at Harvard (DASH Software Development Group, Division of Biostatistics and Epidemiology, DFCI, Boston, MA), which uses the maximum likelihood estimation method, was used. Factors used in modeling were previously defined patient groups, 7 including inpatient status (group I), outpatient status with serious concurrent comorbidity (group II), and other patients with uncontrolled cancer (group III), with the reference group composed of all other patients (group IV); sex; short duration since prior chemotherapy (> 9 days); age 2 30 years, > 40 years, _ 50 years, > 60 years, and -70 years; diagnosis of acute leukemia; bone marrow transplantation; signs or symptoms of abdominal pain; signs or symptoms of mucosal damage (sore throat, odynophagia, perirectal pain, oral ulcers, or perirectal inflammation or tenderness); highest fever within 24 hours after admission > 102'F, > 103'F, and > 104'F; granulocyte count < 300/pL, < 200/ptL, 100/pL, < 50/pL, and 0; absolute monocyte count < 300/piL, < 200/piL, < 1 0 0 /pLL, < 50/p.L, and 0; platelet count > 60,000/pLL, > 40,000/ .LL, and > 20,000/jtL; hematocrit level less than 30%, less than 25%, and less than 20%; renal dysfunction (serum creatinine level 2 2.0 mg/dL); hepatic dysfunction (serum bilirubin level Aggressive chemotherapy was common: 101 patients, all at DFCI, had received bone marrow transplantation, 48 patients had received or were about to receive induction chemotherapy for acute leukemia or chronic myelogenous leukemia, and an additional 30 patients were undergoing intensification therapy after having achieved a complete remission. Nineteen patients who had received no recent prior chemotherapy had neutropenia attributed to invasion of bone marrow by tumor, usually leukemia.
Patients were profoundly neutropenic. The median number of granulocytes when fever and neutropenia occurred was 27/!pL; 385 patients (87%) had granulocyte counts below 300/l.L; 303 (68%) had counts below 100/liL; and 162 (36%) had no granulocytes. The median duration of neutropenia was 7 days for those patients whose neutropenia resolved. The neutropenia of 52 patients did not resolve before death or discharge. Monocyte counts, believed to herald rising granulocyte counts, were also low: the median number of monocytes was 2/p1L, although 92 patients (21%) had counts of 100/ L or more.
Comorbidity and Complications
Of the 444 patients, 268 (60%) were already inpatients when fever and neutropenia developed. Serious concurrent comorbidity at the onset of fever and neutropenia was common, occurring in 119 of 268 patients (44%) who were already hospitalized when fever and neutropenia occurred, and in 43 of 176 who were still outpatients (24%). Although 162 patients (36%) had significant comorbidity, no single type of comorbidity was evident in more than 9% of the patients ( Table 1) . In 38 (88%) of the 43 outpatients presenting with serious comorbidity, the comorbid condition was appar- Table 2 ). No single complication occurred in more than 9% of patients. Multiple complications occurred in 57 patients, 48% of those with any complications (mean, 1.8 complications per patient). Complications occurred at a median of 6 days (range, 1 to 84 days) after presentation. Thirty-four patients, 8% of the study group, died.
Risk Groups
Complications occurred more commonly among all patients in each of groups I, II, and III than among those in group IV (P < .01; Table 3 ). This was apparent at both study sites, although the smaller numbers of patients in groups II, III, and IV resulted in imprecise estimates for those groups at Miriam Hospital alone. Among the 104 group IV patients, five sustained one serious complication each. These included three episodes of hypotension, one of congestive heart failure, and one of interstitial pneumonitis. One episode of hypotension had no clinical consequences and may have been a documentation error (a single blood pressure reading of 70/50 with a pulse of 76, eliciting no documented clinical response). Another, which occurred 24 hours and 5 minutes after presentation (and 18 hours after admission), resolved after brief treatment with intravenous saline. The remaining three complications occurred after at least 7 days of progressive medical illness. One of these, an episode of hypotension, occurred in a patient with very marginal control of his cancer (large-cell non-Hodgkin's lymphoma with tumor regrowth between chemotherapy cycles, recently changed to a phase I experimental therapy). While multiple medical complications and death were common among patients in groups I through III, no group IV patient had more than one complication or died (Table 4 ). In the stepwise multiple logistic regression analysis (Table 5) , the predefined risk groups were the strongest independently significant correlates of complications. Two additional risk factors, short latency from chemotherapy to fever and neutropenia (< 10 days) and age 40 years or greater, correlated with more frequent complications, and one, clinical evidence of mucositis (oral pain or ulcers; odynophagia; or perirectal pain, erythema, or tenderness), correlated with fewer complications. The risk of patients increased with additional risk factors, although with borderline significance for group IV patients (Table 6) .
Other clinical characteristics often evoking concern appeared to add little additional risk when they occurred in the otherwise low-risk group IV patients. No complications occurred among group IV patients with acute leukemia in remission (14 patients), age greater than 65 years (14 patients), bacteremia (11 patients), or liver failure (bilirubin level > 2.0 mg/dL; six patients).
Complications occurred in three of 23 group IV patients (13%) with no granulocytes at presentation, but this increased frequency was not statistically significant in this small group of patients. Patients who presented with a granulocyte count of more than 100/pL were slightly more likely to have complications than those with a lower count, but this did not achieve significance overall or within risk groups.
Medical complications were less frequent overall for patients whose neutropenia resolved in 7 days or less Abbreviation: CI, confidence interval. *Onset of fever and neutropenia within less than 10 days of the beginning of the most recent cytotoxic chemotherapy cycle.
tEvidence of mucosal inflammation, including sore throat, odynophagia, perianal pain, oral ulcers, or perianal tenderness or inflammation.
than for other patients, although the differences were significant only for group I (Table 7) . However, the 16% complication rate was greater than that for group IV, our low-risk group. Only 69 of 200 (35%) of the patients with this relatively brief period of neutropenia would have been classified as low risk (group IV) by our criteria.
DISCUSSION
Appropriate treatments may vary for patient subgroups at substantially different risk. Because cancer patients with fever and neutropenia are considered to have a high overall medical risk, they are generally given treatment as inpatients so that they can be carefully observed. Our studies confirm that this group of patients is at high risk: 27% of the patients in the current study population and 21% in our previous study experienced at least one serious medical complication during the course of hospitalization for fever and neutropenia. However, this risk is not uniform. Using the prediction *Risk factors include onset of fever and neutropenia within less than 10 days of the beginning of the most recent cytotoxic chemotherapy cycle; age 2 40 years; and absence of evidence of mucosal inflammation, including sore throat, odynophagia, perianal pain, oral ulcers, or perianal tenderness or inflammation.
tOverall X 2 for trend, P < .001.
*Overall X ' for trend, P = .05. model validated by the current study, we have been able to identify low-risk patients accurately within the first day of their course. Explicit criteria for prospectively identifying low-risk patients with fever and neutropenia have been previously unavailable. Although the association between good prognosis and data available later in the course, such as an early rise in granulocyte counts, has long been noted,"' 4 these retrospective risk factors are not helpful to the treating physician at the time when a patient presents with fever and neutropenia. Clinical judgment alone has been used to identify low-risk pediatric patients with fever and neutropenia at various points in their hospitalization for early discharge and discontinuation of antibiotics, 14 but such implicit selection criteria are not easily evaluated or exported to other settings and practitioners." 5 Our model to identify low-risk patients was developed in a retrospective study of 261 patients at one specialized referral cancer center. Three clinically determined highrisk groups were defined and were at significantly higher risk than the remaining, low-risk group: inpatients, outpatients with serious concurrent comorbidity, and other outpatients with uncontrolled cancer. Patients in the high-risk groups suffered major complications in 36% of subsequent hospital courses, compared with only 2% of the remaining group of low-risk patients.' The current study validates the original model in an additional 444 patient courses at the first hospital and an additional site, a university-affiliated general medical hospital. To control for potential bias in assessing risk factors and outcomes, we performed an independent, blinded review. In this validation study, patients in the high-risk groups, as defined in the original study, were again at high risk, with a 34% complication rate. The remaining low-risk patient group, which included 59% of all those who were outpatients when they developed fever and neutropenia, had only a 5% risk of developing a medical complication. Further, the complications that did occur in the low-risk group were either transient and asymptomatic, or were heralded by at least 7 days of medical deterioration and easily detectable by appropriate medical follow-up. Thus, none of the complications would have precluded a program of early discharge to medical management at home after 24 hours of hospitalization, which we feel could be an appropriate alternative management for these low-risk patients.
Our model for identifying low-risk patients should be tested in other patient populations. It predicted risk successfully in two settings, a specialized cancer referral center and a community-based, university-affiliated general medical hospital. While absolute risk levels for patient groups in other settings may vary, it is unlikely that group IV patients in community hospital settings would be at substantially greater risk than such patients in the study settings, where aggressive cytotoxic therapy is common. Our criteria for assigning patients to risk groups, while dependent on clinical decisions, could be applied by most physicians who are experienced in the care of cancer patients. Agreement between our raters for concurrent comorbidity (K = .64) and uncontrolled cancer (K = .77) was good; both statistics indicate substantial agreement by the criteria of Landis and Koch 1 6 and the latter, excellent agreement by the criteria of Fleiss. 13 Inappropriate candidates for early discharge programs are patients with fever and neutropenia who are already ill (inpatients, group I), newly ill (outpatients with serious concurrent comorbidity, group II) or at high risk from progressive cancer (outpatients with uncontrolled cancer, group III). The remaining patients are at low risk of subsequent medical complications. The additional factors identified by logistic regression analysis, onset of fever and neutropenia in less than 10 days from chemotherapy, age 40 years or greater, and evidence of mucositis, appeared to modify the risk further in this study. However, this relationship must be confirmed.
Some of our findings are surprising and at variance from previous reports. Many potential risk factors, such as acute leukemia, age 65 years or greater, bacteremia, and liver failure, which may imply high risk, do not alone appear to result in medical complications when occurring in otherwise low-risk group IV patients. However, these factors occurred in small numbers of patients in our study, so further investigation of them will be needed. A granulocyte count of less than 100/p[L alone does not increase risk; the other factors we have identified predominate. The finding that evidence of mucositis predicts fewer medical complications is unexpected and requires confirmation, although it is consistent with a trend observed in our earlier study. We speculate that mucosal injury due to cytotoxic chemotherapy is a self-limited cause of bacteremia and, consequently, fever, which is benign in the setting of appropriate empiric antibiotic therapy. Thus, mucositis may be a relatively innocuous source of fever in cancer patients receiving antitumor therapy compared with less tractable alternative causes. Pizzo et al3 found that patients whose neutropenia resolved within 7 days were at low risk, and Bodey et al have consistently found that improvement in neutropenia in the first week improves prognosis.'1' 7 1 9 We found that while patients with neutropenia of less than 7 days were at lower risk than the remaining patients, they were still at substantial risk (16%) of developing serious medical complications. Further, only one third of all such patients met the criteria for our low-risk group. These possible discrepancies may be due to differences in study design. Our end points, medical complications, differed from those of Pizzo et al (resolution of fever) and Bodey et al (response to therapy and death). In addition, Bodey et al defined the favorable risk factor as improvement of neutropenia, rather than its resolution within 7 days, and defined neutropenia as a granulocyte count of fewer than 1,000/IpL rather than below 500/ýL as in our studies.
Although our prediction model identifies low-risk patients with fever and neutropenia accurately, it cannot supplant clinical vigilance. No model can foresee all circumstances. Treating physicians may discover other, overriding sources of risk in their assessment of apparently low-risk patients. Similarly, although this model successfully predicted later complications using only initial clinical information, appropriate medical follow-up is essential. Actively treated cancer patients are at risk from a variety of potential causes. A patient who is at low risk is not at no risk and should be followed with a low threshold for modifying treatment when clinical circumstances change. Therefore, this model should be tempered by clinical judgment.
Finally, the determination that a patient treated in the hospital is at low risk does not directly imply the same low risk if that patient is treated at home. The safety of home therapy after 24 hours for low-risk patients must be demonstrated by pilot studies. If the pilot studies are successful, a large, randomized trial will be required to demonstrate the safety and potential benefit of early discharge to home therapy for low-risk cancer patients with fever and neutropenia.
